- Title
- Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis
- Creator
- Maltby, Vicki; Xavier, Alexandre; Slee, Mark; van der Mei, Ingrid A.; Taylor, Bruce V.; Ponsonby, Anne-Louise; Jagodic, Maja; Lea, Rodney; Lechner-Scott, Jeannette; Ewing, Ewoud; Campagna, Maria-Pia; Sampangi, Sandeep; Scott, Rodney J.; Butzkueven, Helmut; Jokubaitis, Vilija; Kular, Lara; Bos, Steffan
- Relation
- Neurology Vol. 101, Issue 7, p. e679-e689
- Publisher Link
- http://dx.doi.org/10.1212/WNL.0000000000207489
- Publisher
- Wolters Kluwer
- Resource Type
- journal article
- Date
- 2023
- Description
- Background and Objectives: In multiple sclerosis (MS), accelerated aging of the immune system (immunosenescence) may be associated with disease onset or drive progression. DNA methylation (DNAm) is an epigenetic factor that varies among lymphocyte subtypes, and cell-specific DNAm is associated with MS. DNAm varies across the life span and can be used to accurately estimate biological age acceleration, which has been linked to a range of morbidities. The objective of this study was to test for cell-specific epigenetic age acceleration (EAA) in people with MS. Methods: This was a case-control study of EAA using existing DNAm data from several independent previously published studies. Data were included if .idat files from Illumina 450K or EPIC arrays were available for both a case with MS and an age-matched and sex-matched control, from the same study. Multifactor statistical modeling was performed to assess the primary outcome of EAA. We explored the relationship of EAA and MS, including interaction terms to identify immune cell-specific effects. Cell-sorted DNA methylation data from 3 independent datasets were used to validate findings. Results: We used whole blood DNA methylation data from 583 cases with MS and 643 non-MS controls to calculate EAA using the GrimAge algorithm. The MS group exhibited an increased EAA compared with controls (approximately 9 mths, 95% CI 3.6–14.4), p = 0.001). Statistical deconvolution showed that EAA is associated with MS in a B cell–dependent manner (βint = 1.7, 95% CI 0.3–2.8), p = 0.002), irrespective of B-cell proportions. Validation analysis using 3 independent datasets enriched for B cells showed an EAA increase of 5.1 years in cases with MS compared with that in controls (95% CI 2.8–7.4, p = 5.5 × 10−5). By comparison, there was no EAA difference in MS in a T cell–enriched dataset. We found that EAA was attributed to the DNAm surrogates for Beta-2-microglobulin (difference = 47,546, 95% CI 10,067–85,026; p = 7.2 × 10−5), and smoking pack-years (difference = 8.1, 95% CI 1.9–14.2, p = 0.002). Discussion: This study provides compelling evidence that B cells exhibit marked EAA in MS and supports the hypothesis that premature B-cell immune senescence plays a role in MS. Future MS studies should focus on age-related molecular mechanisms in B cells.
- Subject
- immunosenescence; DNA methylation; multiple sclerosis; aging
- Identifier
- http://hdl.handle.net/1959.13/1492101
- Identifier
- uon:53246
- Identifier
- ISSN:0028-3878
- Language
- eng
- Reviewed
- Hits: 2451
- Visitors: 2437
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|